Differential liver function at cessation of atezolizumab-bevacizumab versus lenvatinib in HCC: a multicenter, propensity-score matched comparative study

BackgroundAtezolizumab+bevacizumab (AB) and lenvatinib have been proposed as first-line treatment options for patients with advanced hepatocellular carcinoma (HCC), but comparative efficacy and associated factors are controversial.Materials and methodsThis real-world multicenter study analysed patie...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Ji Won Han, Pil Soo Sung, Jae-Sung Yoo, Hee Sun Cho, Soon Kyu Lee, Hyun Yang, Ji Hoon Kim, Heechul Nam, Hae Lim Lee, Hee Yeon Kim, Sung Won Lee, Do Seon Song, Myeong Jun Song, Jung Hyun Kwon, Chang Wook Kim, Si Hyun Bae, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Frontiers Media S.A. 2024-02-01
Ráidu:	Frontiers in Oncology
Fáttát:	HCC atezolizumab plus bevacizumab lenvatinib residual liver function survival
Liŋkkat:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1372007/full
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!